ATE142494T1 - 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel - Google Patents
2-arylthiazolderivat sowie dieses enthaltendes arzneimittelInfo
- Publication number
- ATE142494T1 ATE142494T1 AT91920699T AT91920699T ATE142494T1 AT E142494 T1 ATE142494 T1 AT E142494T1 AT 91920699 T AT91920699 T AT 91920699T AT 91920699 T AT91920699 T AT 91920699T AT E142494 T1 ATE142494 T1 AT E142494T1
- Authority
- AT
- Austria
- Prior art keywords
- arylthiazole
- product containing
- medicinal product
- alkyl
- optionally protected
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Residential Or Office Buildings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33014790 | 1990-11-30 | ||
| JP21658691 | 1991-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE142494T1 true ATE142494T1 (de) | 1996-09-15 |
Family
ID=26521514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91920699T ATE142494T1 (de) | 1990-11-30 | 1991-11-29 | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5614520A (de) |
| EP (1) | EP0513379B1 (de) |
| JP (1) | JP2725886B2 (de) |
| KR (1) | KR100221041B1 (de) |
| AT (1) | ATE142494T1 (de) |
| AU (1) | AU645867B2 (de) |
| CA (1) | CA2073981C (de) |
| DE (2) | DE69122084T2 (de) |
| DK (1) | DK0513379T3 (de) |
| ES (1) | ES2092580T3 (de) |
| HU (1) | HU218942B (de) |
| SG (1) | SG86971A1 (de) |
| WO (1) | WO1992009279A1 (de) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5294630A (en) * | 1992-07-07 | 1994-03-15 | Eli Lilly And Company | Treatment of inflammatory bowel disease |
| US5436258A (en) * | 1992-09-09 | 1995-07-25 | Eli Lilly And Company | Prevention of bone resorption |
| EP0695742A1 (de) | 1994-08-03 | 1996-02-07 | Hoechst Aktiengesellschaft | Fullerenazirin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung |
| US5843969A (en) * | 1995-04-07 | 1998-12-01 | Teijin Limited | Protecting agent for organ or tissue |
| KR970061878A (ko) * | 1996-02-23 | 1997-09-12 | 성재갑 | 신규한 아릴티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 하는 제초제 조성물 |
| US6156748A (en) * | 1996-10-07 | 2000-12-05 | Eli Lilly And Company | Compounds useful as neuro-protective agents |
| US6472387B1 (en) | 1996-10-07 | 2002-10-29 | Eli Lilly And Company | Methods of using compounds as neuro-protective agents |
| ID21775A (id) * | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| JP2001519341A (ja) | 1997-10-06 | 2001-10-23 | イーライ・リリー・アンド・カンパニー | 神経保護剤として有用な新規化合物 |
| JP3547707B2 (ja) * | 1998-06-19 | 2004-07-28 | 帝人株式会社 | ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体およびその製造方法 |
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| EP1143951A3 (de) | 1998-09-21 | 2002-02-06 | University Of Florida Research Foundation, Inc. | Mittel gegen malaria |
| US6410562B1 (en) | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| US6348324B1 (en) | 1999-01-21 | 2002-02-19 | Hypoguard America Limited | Composition and device for detecting leukocytes in urine |
| US6528652B1 (en) | 1999-01-21 | 2003-03-04 | Chronimed | Composition and device for detecting leukocytes in urine |
| AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| DE10106852A1 (de) | 2001-02-14 | 2002-09-05 | T Luger | Entzündungshemmende Verbindungen |
| JP4917243B2 (ja) * | 2001-05-23 | 2012-04-18 | 日本曹達株式会社 | チアゾール化合物の製造方法 |
| WO2003082279A1 (en) | 2002-03-28 | 2003-10-09 | Teijin Limited | Solid preparation containing single crystal form |
| US7273866B2 (en) * | 2002-12-20 | 2007-09-25 | Bristol-Myers Squibb Company | 2-aryl thiazole derivatives as KCNQ modulators |
| US6933308B2 (en) * | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
| US7208514B2 (en) | 2003-03-13 | 2007-04-24 | Mitsubishi Pharma Corporation | Tumorigenesis inhibitor |
| US20050027128A1 (en) * | 2003-07-30 | 2005-02-03 | Robbins Timothy A. | Substituted thiazoles |
| AU2003270473A1 (en) | 2003-09-09 | 2005-04-27 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7485657B2 (en) * | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| JP4914210B2 (ja) * | 2004-06-14 | 2012-04-11 | 日本ケミファ株式会社 | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 |
| WO2006022375A1 (ja) | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | ２－フェニルチオフェン誘導体 |
| US7820700B2 (en) | 2004-08-27 | 2010-10-26 | Astellas Pharma Inc. | 2-phenylpyridine derivative |
| EP1812071A2 (de) * | 2004-10-13 | 2007-08-01 | PTC Therapeutics, Inc. | Verbindungen zur nonsense-unterdrückung und verwendung dieser verbindungen für die herstellung eines medikaments zur behandlung somatischer mutationsbedingter erkrankungen |
| US7790720B2 (en) | 2005-03-31 | 2010-09-07 | Ucb Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| MX2007012226A (es) | 2005-04-04 | 2007-12-10 | Univ Florida | Analogos de polieter de desferritiocina. |
| WO2006121995A2 (en) * | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| JP2009501721A (ja) * | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
| US20070167454A1 (en) * | 2005-08-03 | 2007-07-19 | Christopher Lademacher | Methods for treating hypertension |
| CA2623327A1 (en) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2007043457A1 (ja) * | 2005-10-07 | 2007-04-19 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体 |
| CN1954814A (zh) * | 2005-10-26 | 2007-05-02 | 重庆医药工业研究院有限责任公司 | 一种具有协同作用治疗痛风的药物组合物及其制备方法 |
| CN100430055C (zh) * | 2005-11-11 | 2008-11-05 | 天津泰普药品科技发展有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
| MX2008010646A (es) * | 2006-02-24 | 2008-10-14 | Astellas Pharma Inc | Agente para tratar o prevenir ulcera digestiva. |
| EP2030974B1 (de) * | 2006-06-13 | 2016-02-17 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Thiazol- nichtnukleosid-verbindungen, ihre herstellung, pharmazeutische zusammensetzung und ihre verwendung als antivirale mittel |
| CA2658342A1 (en) * | 2006-07-19 | 2008-01-24 | Nippon Medical School Foundation | Therapeutic agent for amyotrophic lateral sclerosis |
| CN101812035B (zh) * | 2006-09-07 | 2012-03-21 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
| CN101139325B (zh) * | 2006-09-07 | 2010-05-12 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
| US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| KR20150024919A (ko) * | 2006-11-13 | 2015-03-09 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 |
| CN102093308B (zh) * | 2006-12-07 | 2012-08-29 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
| CN102093309B (zh) * | 2006-12-07 | 2012-07-04 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
| CN1970547B (zh) * | 2006-12-07 | 2011-04-06 | 重庆医药工业研究院有限责任公司 | 非布司他的晶型及其制备方法 |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| WO2008115433A1 (en) | 2007-03-15 | 2008-09-25 | University Of Florida | Desferrithiocin polyether analogues |
| WO2008126772A1 (ja) * | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | 高血圧治療剤 |
| EP2786993B1 (de) | 2007-08-13 | 2017-11-15 | Monsanto Technology LLC | Zusammensetzungen und Verfahren zur Kontrolle von Nematoden |
| CN102186824B (zh) * | 2008-10-15 | 2014-03-12 | 橘生药品工业株式会社 | 稠环衍生物及其医药用途 |
| JP5580204B2 (ja) * | 2008-10-15 | 2014-08-27 | キッセイ薬品工業株式会社 | ビアリールイソニコチン酸誘導体及びその医薬用途 |
| CN101759656B (zh) * | 2008-12-12 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 非布司他新晶型及其制备方法 |
| CN101768150B (zh) * | 2009-01-05 | 2014-08-06 | 常州市第四制药厂有限公司 | 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法 |
| CN101781270B (zh) * | 2009-01-20 | 2013-03-27 | 重庆医药工业研究院有限责任公司 | 一种高纯度的非布司他及其制备方法 |
| US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| CN101475541B (zh) * | 2009-02-09 | 2011-05-25 | 扬州哈泰克材料有限公司 | 4-甲基噻唑-5-羧酸的一种制备方法 |
| US8952174B2 (en) | 2009-02-27 | 2015-02-10 | Teijin Pharma Limited | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst |
| CN101580495A (zh) * | 2009-05-25 | 2009-11-18 | 沈阳药科大学 | 5-取代苯基-3-异噁唑甲酸及其酯类化合物、组合物及其制备方法 |
| BRPI1011014A2 (pt) | 2009-06-09 | 2019-09-24 | Teijin Pharma Ltd | método de produção. |
| DE202010017868U1 (de) | 2009-06-10 | 2012-11-28 | Teva Pharmaceutical Industries Ltd. | Kristalline Formen von Febuxostat |
| EP2266966A1 (de) | 2009-06-11 | 2010-12-29 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Febuxostat |
| CN101928259B (zh) * | 2009-06-18 | 2012-10-03 | 南京海辰药业有限公司 | 2-芳基噻唑衍生物及其药物组合物 |
| US9545445B2 (en) | 2009-06-26 | 2017-01-17 | Teijin Pharma Limited | Therapeutic drug for hypertension or prehypertension |
| CN103936689B (zh) * | 2009-07-17 | 2016-08-17 | 北京利乐生制药科技有限公司 | 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法 |
| EP2483256A1 (de) | 2009-09-10 | 2012-08-08 | Teva Pharmaceutical Industries Ltd. | Verfahren zur herstellung von febuxostat |
| IT1395936B1 (it) * | 2009-09-29 | 2012-11-02 | Dipharma Francis Srl | Sali di febuxostat |
| TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| WO2011073617A1 (en) | 2009-12-14 | 2011-06-23 | Cipla Limited | Processes for the preparation of febuxostat and salts thereof |
| WO2011080651A2 (en) | 2009-12-31 | 2011-07-07 | Ranbaxy Laboratories Limited | Polymorphic forms of febuxostat |
| WO2011101867A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Substantially pure salts of febuxostat and processes for preparation thereof |
| US20130012553A1 (en) * | 2010-02-19 | 2013-01-10 | Macdonald Patricia | Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors |
| CA2792036A1 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid |
| US8969582B2 (en) | 2010-04-29 | 2015-03-03 | Dr. Reddy's Laboratories Ltd. | Preparation of febuxostat |
| IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
| IT1400310B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e statine e loro uso. |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| IT1400609B1 (it) | 2010-05-10 | 2013-06-14 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e metformina e loro uso. |
| PE20170306A1 (es) * | 2010-06-16 | 2017-05-06 | Takeda Pharmaceuticals Usa Inc | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| JP5709146B2 (ja) | 2010-06-16 | 2015-04-30 | アルデア バイオサイエンシーズ インク． | フェニルチオ酢酸化合物、組成物、および、その使用方法 |
| RU2013103366A (ru) | 2010-06-25 | 2014-07-27 | Тейдзин Фарма Лимитед | Терапевтическое средство с замедленным высвобождением для гипертонии и почечной дисфункции |
| AR081267A1 (es) * | 2010-07-13 | 2012-07-18 | Interquim Sa | Procedimiento de obtencion de la forma cristalina a del febuxostat |
| EP2598494B1 (de) | 2010-07-30 | 2014-11-26 | Ranbaxy Laboratories Limited | Verbessertes verfahren zur herstellung von febuxostat |
| WO2012020272A2 (en) | 2010-08-13 | 2012-02-16 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New salts, polymorphs and solvates of a pharmaceutical active ingredient |
| AU2011294204B2 (en) | 2010-08-27 | 2015-07-23 | Teijin Limited | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound |
| US20130172571A1 (en) | 2010-09-08 | 2013-07-04 | Natco Pharma Limited | Process to prepare ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate |
| JP5978216B2 (ja) | 2010-09-10 | 2016-08-24 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | テオフィリンとフェブキソスタットの併用療法のための方法 |
| US20130303780A1 (en) | 2010-11-08 | 2013-11-14 | Siva Rama Prasad Vellanki | Process for the preparation of 2-arylthiazole derivatives |
| WO2012073259A1 (en) | 2010-12-02 | 2012-06-07 | Indoco Remedies Limited | Novel process for the preparation of febuxostat |
| WO2012098501A1 (en) | 2011-01-21 | 2012-07-26 | Ranbaxy Laboratories Limited | Febuxostat co-crystals |
| WO2012109573A1 (en) * | 2011-02-11 | 2012-08-16 | Purdue Research Foundation | Substituted thiazoles for use as antiviral agents |
| CN102643249A (zh) * | 2011-02-18 | 2012-08-22 | 苏州波锐生物医药科技有限公司 | 2-芳基噻唑衍生物,其可药用盐及用途 |
| WO2012131590A1 (en) | 2011-03-31 | 2012-10-04 | Sandoz Ag | An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof |
| AU2012241378A1 (en) | 2011-04-15 | 2013-10-31 | Sun Pharmaceutical Industries Limited | Febuxostat solid dispersion |
| WO2012153313A1 (en) | 2011-05-11 | 2012-11-15 | Ranbaxy Laboratories Limited | Pharmaceutical composition of febuxostat |
| WO2012172461A1 (en) | 2011-06-13 | 2012-12-20 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of febuxostat |
| WO2013050996A2 (en) * | 2011-10-05 | 2013-04-11 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| TW201328692A (zh) * | 2011-10-11 | 2013-07-16 | Univ Osaka | 脫髓鞘疾病之治療劑及預防劑 |
| CA2852490A1 (en) | 2011-11-03 | 2013-05-10 | Ardea Biosciences, Inc. | 3,4-di-substituted pyridine compound to reduce serum uric acid levels |
| CN104114545B (zh) * | 2011-11-15 | 2018-06-01 | 迈兰实验室有限公司 | 用于制备非布索坦多晶型物的方法 |
| BR112014014544A2 (pt) | 2011-12-16 | 2017-06-13 | Univ Florida | usos de análogos de 4'-desferritiocina |
| WO2013088449A1 (en) | 2011-12-16 | 2013-06-20 | Natco Pharma Limited | Stable crystal form of febuxostat and process for the preparation thereof |
| EP2606888A1 (de) * | 2011-12-19 | 2013-06-26 | Dompe' S.P.A. | TRPM8-Antagonisten |
| ES2676884T3 (es) * | 2011-12-19 | 2018-07-25 | Dompé Farmaceutici S.P.A. | Antagonistas de TRPM8 |
| AU2013212865A1 (en) * | 2012-01-27 | 2014-08-14 | National University Corporation Tottori University | Therapeutic agent for diabetes |
| EP2925306A1 (de) | 2012-07-12 | 2015-10-07 | Alembic Pharmaceuticals Limited | Pharmazeutische zusammensetzung von febuxostat |
| EP2692342A1 (de) | 2012-07-30 | 2014-02-05 | Interquim, S.A. | Verfahren zur Herstellung pharmazeutischer Zusammensetzungen mit Febuxostat in Tablettenform |
| CN103130744B (zh) * | 2012-08-28 | 2014-10-15 | 沈阳药科大学 | 一种硒唑甲酸类化合物及其制备方法和用途 |
| WO2014057461A1 (en) | 2012-10-11 | 2014-04-17 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form g of febuxostat |
| RU2627591C2 (ru) * | 2012-10-23 | 2017-08-09 | Тейдзин Фарма Лимитед | Терапевтический или профилактический агент для синдрома распада опухоли |
| CN103848798B (zh) * | 2012-11-30 | 2016-01-06 | 镇江新元素医药科技有限公司 | 2-芳基硒唑化合物及其药物组合物 |
| US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| CN103936693B (zh) * | 2013-01-22 | 2016-06-15 | 沈阳药科大学 | 2-(3-氰基-4-取代苯基)-4-甲基-1,3-硒唑-5-甲酸及其酯类化合物和制备方法 |
| TWI606048B (zh) * | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| CN103333134B (zh) * | 2013-03-01 | 2016-02-24 | 沈阳药科大学 | 2-(3-氰基-4-烷氧基)苯基-4-取代噻唑-5-甲酸类化合物、组合物及其制备方法和用途 |
| CN104163782A (zh) * | 2013-05-17 | 2014-11-26 | 重庆圣华曦药业股份有限公司 | 一种制备3，4-取代的硫代苯甲酰胺的方法及其在非布司他合成中的应用 |
| WO2014192977A1 (ja) * | 2013-05-31 | 2014-12-04 | 帝人ファーマ株式会社 | チアゾール誘導体 |
| ES2772131T3 (es) | 2013-08-07 | 2020-07-07 | Pharmathen Sa | Un nuevo proceso para la preparación de Febuxostat |
| CN104418822B (zh) * | 2013-08-22 | 2016-12-28 | 南京华威医药科技开发有限公司 | 具有黄嘌呤氧化酶抑制活性的化合物及其用途 |
| CN103524456B (zh) * | 2013-09-30 | 2016-06-01 | 南京华威医药科技开发有限公司 | 一种硒唑甲酸类化合物及其盐 |
| WO2015077655A1 (en) | 2013-11-22 | 2015-05-28 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| EP2881116A1 (de) | 2013-12-05 | 2015-06-10 | Ranbaxy Laboratories Limited | Febuxostatzusammensetzung |
| CA2948792A1 (en) * | 2014-05-13 | 2015-11-19 | Teijin Pharma Limited | Novel crystalline polymorphs of pyridine derivative and method for producing the same |
| EP3157918B1 (de) | 2014-06-23 | 2019-03-27 | Dompé farmaceutici S.p.A. | 2-aryl-4-hydroxy-1,3-thiazolderivate als trpm8-antagonisten zur behandlung von neuralgie, schmerzen, copd und asthma. |
| JP2017165653A (ja) * | 2014-07-30 | 2017-09-21 | 帝人ファーマ株式会社 | アゾールカルボン酸誘導体 |
| KR20170033321A (ko) * | 2014-07-30 | 2017-03-24 | 데이진 화-마 가부시키가이샤 | 아졸벤젠 유도체의 결정 |
| US20170217948A1 (en) | 2014-07-30 | 2017-08-03 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
| CA2956553C (en) | 2014-07-30 | 2023-03-21 | Teijin Pharma Limited | A 1h-1,2,3,4-tetrazole benzene derivative, crystalline forms thereof, and its use as a xanthine oxidase inhibitor |
| CZ27857U1 (cs) | 2014-12-12 | 2015-02-23 | Zentiva, K.S. | Formulace obsahující tuhý roztok febuxostatu |
| EP3263109B1 (de) | 2015-02-24 | 2020-06-17 | National University Corporation Tottori University | Arzneimittel zur prävention und/oder behandlung von demenz |
| US9809586B2 (en) | 2015-03-28 | 2017-11-07 | Wisconsin Alumni Research Foundation | Inhibitors of collagen prolyl 4-hydroxylase |
| US10570104B2 (en) | 2015-04-27 | 2020-02-25 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
| EP3344604B1 (de) * | 2015-09-02 | 2020-11-04 | Sunshine Lake Pharma Co., Ltd. | Carboxy-substituierte (hetero) aromatische ringderivate und herstellungsverfahren und verwendungen davon |
| EP3417858B8 (de) | 2016-02-19 | 2020-12-30 | National University Corporation Tottori University | Therapeutikum oder prophylaktikum gegen demenz |
| CN106146419A (zh) * | 2016-08-01 | 2016-11-23 | 沈阳药科大学 | 黄嘌呤氧化酶抑制剂 |
| CN108358866B (zh) * | 2017-01-12 | 2021-03-23 | 江西同和药业股份有限公司 | 一种非布司他中间体的制备方法及其在制备非布司他中的应用 |
| CN110066258A (zh) | 2018-01-23 | 2019-07-30 | 湘北威尔曼制药股份有限公司 | 噻唑-5-甲酸衍生物及其制备方法与应用 |
| CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
| CN109810073B (zh) * | 2019-02-28 | 2023-01-06 | 南京海辰药业股份有限公司 | 4-芳基噻唑衍生物及其药物组合物 |
| CN114341120A (zh) | 2019-08-21 | 2022-04-12 | 国立大学法人东京大学 | Abcc11抑制剂 |
| CN113024534B (zh) * | 2019-12-24 | 2023-03-21 | 武汉光谷亚太医药研究院有限公司 | 2-吡啶基噻唑衍生物及其应用 |
| CN115572272B (zh) * | 2022-11-15 | 2024-05-07 | 湖北华世通生物医药科技有限公司 | 非布司他及其醛基酯类中间体的制备方法 |
| WO2025221114A1 (ko) * | 2024-04-17 | 2025-10-23 | 연세대학교 산학협력단 | 신규한 페북소스타트 유도체 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
| CA962269A (en) * | 1971-05-05 | 1975-02-04 | Uniroyal Ltd. | Thiazoles, and their use as insecticides |
| DE2125251A1 (en) * | 1971-05-21 | 1972-11-30 | Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen | Monoazo dispersion dyes - contg a thiazolyl substit in 2-position for use on synthetic fibres |
| DE2125193C3 (de) * | 1971-05-21 | 1980-08-14 | Basf Ag, 6700 Ludwigshafen | 4-Nitro-2-thiazolyl-1 -aminobenzole und Verfahren zu ihrer Herstellung |
| US3852293A (en) * | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
| US4020080A (en) * | 1974-07-01 | 1977-04-26 | Eastman Kodak Company | Oxadiazolylphenyl aromatic ester compounds and their use as ultraviolet stabilizer in organic compositions |
| US4363813A (en) * | 1979-07-09 | 1982-12-14 | Kureha Kagaku Kogyo Kabushiki Kaisha | 2-(3,4,5-Trimethoxyphenyl)-4,5-disubstituted thiazoles |
| DE3002989A1 (de) * | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
| US4346094A (en) * | 1980-09-22 | 1982-08-24 | Eli Lilly And Company | 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels |
| JPS5772975A (en) * | 1980-10-24 | 1982-05-07 | Kureha Chem Ind Co Ltd | 2-substituted phenylthiazole derviative, and medicine for peptic ulcer containing said derivative as active component |
| DE3141430A1 (de) * | 1981-10-19 | 1983-05-05 | Basf Ag, 6700 Ludwigshafen | Heterocyclisch substiutierte azofarbstoffe |
| US4571402A (en) * | 1982-06-22 | 1986-02-18 | Schering Corporation | Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
| US4528291A (en) * | 1982-06-22 | 1985-07-09 | Schering Corporation | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility |
| JPS5925381A (ja) * | 1982-06-30 | 1984-02-09 | Hisamitsu Pharmaceut Co Inc | 新規なフエニル酢酸誘導体 |
| JPH0725754B2 (ja) * | 1986-01-30 | 1995-03-22 | 富山化学工業株式会社 | 新規なチアゾール化合物またはその塩 |
| JPH01110683A (ja) * | 1986-09-27 | 1989-04-27 | Sawai Seiyaku Kk | Ｎ−テトラゾリルチアゾールカルボキシアミド誘導体およびその用途 |
| JPS63112572A (ja) * | 1986-10-30 | 1988-05-17 | Yamanouchi Pharmaceut Co Ltd | ２（３ｈ）−チアゾロン誘導体 |
| JPS63112574A (ja) * | 1986-10-30 | 1988-05-17 | Yamanouchi Pharmaceut Co Ltd | ４−トリ置換フエニル−２（３ｈ）−チアゾロン誘導体 |
| WO1990009381A1 (en) * | 1989-02-08 | 1990-08-23 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| JPH02229190A (ja) * | 1989-03-02 | 1990-09-11 | Taisho Pharmaceut Co Ltd | アゾール誘導体 |
| US5244867A (en) * | 1989-09-26 | 1993-09-14 | Basf Aktiengesellschaft | Oxazole- and thiazolecarboxamides |
-
1991
- 1991-11-29 AT AT91920699T patent/ATE142494T1/de not_active IP Right Cessation
- 1991-11-29 SG SG9603299A patent/SG86971A1/en unknown
- 1991-11-29 CA CA002073981A patent/CA2073981C/en not_active Expired - Lifetime
- 1991-11-29 JP JP4500083A patent/JP2725886B2/ja not_active Expired - Lifetime
- 1991-11-29 DE DE69122084T patent/DE69122084T2/de not_active Expired - Lifetime
- 1991-11-29 ES ES91920699T patent/ES2092580T3/es not_active Expired - Lifetime
- 1991-11-29 WO PCT/JP1991/001670 patent/WO1992009279A1/ja not_active Ceased
- 1991-11-29 EP EP91920699A patent/EP0513379B1/de not_active Expired - Lifetime
- 1991-11-29 KR KR1019920701809A patent/KR100221041B1/ko not_active Expired - Lifetime
- 1991-11-29 HU HU9202265A patent/HU218942B/hu unknown
- 1991-11-29 AU AU89522/91A patent/AU645867B2/en not_active Expired
- 1991-11-29 DK DK91920699.5T patent/DK0513379T3/da active
- 1991-11-29 DE DE122008000051C patent/DE122008000051I1/de active Pending
-
1995
- 1995-01-30 US US08/380,214 patent/US5614520A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2725886B2 (ja) | 1998-03-11 |
| HU9202265D0 (en) | 1992-10-28 |
| EP0513379B1 (de) | 1996-09-11 |
| DE69122084D1 (de) | 1996-10-17 |
| DE122008000051I1 (de) | 2009-02-05 |
| KR100221041B1 (ko) | 1999-09-15 |
| AU8952291A (en) | 1992-06-25 |
| AU645867B2 (en) | 1994-01-27 |
| CA2073981A1 (en) | 1992-05-31 |
| DK0513379T3 (da) | 1996-09-30 |
| WO1992009279A1 (fr) | 1992-06-11 |
| DE69122084T2 (de) | 1997-04-03 |
| KR927003052A (ko) | 1992-12-17 |
| HU218942B (hu) | 2001-01-29 |
| EP0513379A4 (en) | 1993-09-01 |
| SG86971A1 (en) | 2002-03-19 |
| EP0513379A1 (de) | 1992-11-19 |
| ES2092580T3 (es) | 1996-12-01 |
| CA2073981C (en) | 2002-01-08 |
| HUT63838A (en) | 1993-10-28 |
| US5614520A (en) | 1997-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE142494T1 (de) | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel | |
| ATE194335T1 (de) | 4,5-diaryloxazol-derivate | |
| DE69528005D1 (de) | Prolineamid-Derivate | |
| HUT65890A (en) | Process for preparation of aromatic amidine derivatives and pharmaceutical compositions containing them | |
| ATE150749T1 (de) | Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel | |
| RU94040163A (ru) | Гетероциклические производные карбоновой кислоты и их соли и фармацевтическая композиция с антифибротической или тормозящей пролилгидроксилазу или биосинтез коллагена активностью | |
| ATE226574T1 (de) | 4,6-diarylpyrimidin-derivate und deren salze | |
| ATE227293T1 (de) | 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one | |
| HUP9802762A2 (hu) | Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| NO306992B1 (no) | Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene | |
| NO923126D0 (no) | Preparat og metode for behandling av canser | |
| NO307464B1 (no) | Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter | |
| HU9300202D0 (en) | Benzo-pyrane derivatives, pharmaceutical preparatives containing them as active substance as well as method for producing them | |
| IL106993A (en) | Benzenalkanoic acid derivatives and pharmaceutical compositions containing them | |
| IL110894A0 (en) | Cephem derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | |
| NO20020804D0 (no) | Nye A-500359-derivater | |
| DE69329184D1 (de) | Alkylsubstituierte heterocyclische Verbindungen | |
| AR029937A1 (es) | Utilizacion de derivados de 2-aminotiazolina para la preparacion de medicamentos, derivados de 2-aminotiazolina y sus procedimientos de preparacion, las composiciones farmaceuticas que contienen dichos derivados, los compuestos intermediarios en la preparacion de dichos derivados y los procedimiento | |
| DE69300318D1 (de) | Flavonderivate. | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| DE69401521D1 (de) | Piperidin-Derivate mit antihistaminischer und antileukomenischer Wirkung | |
| EP0601181A4 (en) | Benzofuran derivative and pharmaceutical composition. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEIH | Change in the person of patent owner | ||
| EELA | Cancelled due to lapse of time |